Fetal growthretardation: modern view on pharmacological correction

Purpose . Comparative analysis of the effectiveness of pharmacological correction of fetal growth retardation using monotherapy with diosmin and dipyridamole. Materials and methods . A retrospective and prospective examination of 160 pregnant women with a singleton pregnancy at a gestational age of 28 to 36 weeks with a confirmed diagnosis of fetal growth restriction was conducted. An extensive collection and analysis of anamnesis, general clinical and obstetric-gynecological examination, laboratory and ultrasound methods were carried out. Newborns were assessed using Apgar scores at birth and 5 min later. In the early neonatal period, congenital and incident pathological syndromes were assessed. Results . In patients receiving diosmin, a decrease in the resistance index of the right and left uterine arteries was achieved to 0.42±0.002 and 0.45±0.002, respectively, and for the umbilical cord artery to 0.52±0.02, which is significantly lower than in the group of patients taking dipyridamole. A positive effect of diosmin on the intrauterine state of the fetus was revealed, which is realized in the form of an increase in its compensatory abilities to adapt to chronic hypoxia in a significantly higher percentage of cases compared to dipyridamole. Conclusion . The data obtained demonstrate the difference in the pharmacokinetics of these drugs: diosmin equally improves both maternal and fetal blood flow, which is most valuable in the treatment of fetal growth restriction, while dipyridamole affects only uterine blood flow.